ICD-10 Coding for Euglycemic Diabetic Ketoacidosis(E10.1, E10.10, E10.10B)
Learn about the ICD-10 coding for euglycemic diabetic ketoacidosis, including documentation requirements and coding pitfalls.
Complete code families applicable to Euglycemic Diabetic Ketoacidosis
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| E10.10 | Type 1 diabetes mellitus with ketoacidosis without coma | Use when EDKA is diagnosed in a patient with type 1 diabetes. |
|
| E11.10 | Type 2 diabetes mellitus with ketoacidosis without coma | Use when EDKA is diagnosed in a patient with type 2 diabetes. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutEuglycemic Diabetic Ketoacidosis
Alternative codes to consider when ruling out similar conditions
Use only if documentation explicitly states non-diabetic starvation ketosis.
Documentation & Coding Risks
Avoid these common issues when documenting Euglycemic Diabetic Ketoacidosis.
Failure to document drug-induced EDKA
Impact
Clinical: Incomplete clinical picture of drug effects., Regulatory: Non-compliance with coding standards., Financial: Potential loss of reimbursement for drug-related complications.
Mitigation
Review medication lists for SGLT2 inhibitors., Ensure adverse effects are documented.
Misclassification of EDKA as hyperglycemic DKA
Impact
Reimbursement: Incorrect DRG assignment may affect reimbursement., Compliance: Non-compliance with coding guidelines., Data Quality: Inaccurate clinical data representation.
Mitigation
Ensure documentation specifies normal glucose levels and presence of acidosis.
Omission of SGLT2 inhibitor adverse effect code
Impact
Reimbursement: Potential underpayment due to incomplete coding., Compliance: Failure to capture drug-induced conditions., Data Quality: Incomplete data on drug-related adverse effects.
Mitigation
Include T45.1X5A when EDKA is induced by SGLT2 inhibitors.
Incomplete documentation of EDKA
Impact
Failure to document all required elements for EDKA coding.
Mitigation
Implement EHR prompts for required documentation elements.